Showing results (1321-1330 of 14,091) with videos related to
Sort By:
Pageof 1,410
Gynecologic Oncology|October 1, 1992
The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancerN Gleeson, R Gonsalves, J BonnarGynecologic Oncology|November 19, 2009
Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimensTommaso Susini, Cecilia Bussani, Giulia Marini, et al.Gynecologic Oncology|November 21, 2009
Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRIEun Ji Nam, Mi Jin Yun, Young Taik Oh, et al.Gynecologic Oncology|December 22, 2009
RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9Yang Zhao, Zhi-hong Zong, Hui-mian XuGynecologic Oncology|May 13, 2017
Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genesMelissa K Frey, Gabriella Sandler, Rachel Sobolev, et al.Gynecologic Oncology|May 13, 2017
Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancerMarta De Donato, Marco Petrillo, Enrica Martinelli, et al.Gynecologic Oncology|May 13, 2017
Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancerKevin H Eng, Kayla Morrell, Kristen Starbuck, et al.Gynecologic Oncology|April 9, 2018
Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancerJoyce Liu, Shibani Nicum, Peter Reichardt, et al.Gynecologic Oncology|April 1, 1991
Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiationJ A Ledermann, A J Dembo, J F Sturgeon, et al.Gynecologic Oncology|April 1, 1991
Anticancer activity of the combination of cisplatin and etoposide in endometrial cancer-bearing nude miceM Suzuki, I Aida, I Sekiguchi, et al.Pageof 1,410